Posted on 7/31/17
Better Buy: Cara Therapeutics Inc. vs. GW Pharmaceuticals plc
Cara Therapeutics Inc. (NASDAQ:CARA), and GW Pharmaceuticals plc (NASDAQ:GWPH)often get lumped in with a stack of risky marijuana stocks, because both are developing drugs derived from . . .
Posted on 7/31/17
NIVEA Men & Real Madrid C.F. Team Up for El Clásico Miami
WILTON, Conn.--(BUSINESS WIRE)--Building on the brand’s global sponsorship of Real Madrid C.F, NIVEA Men, the world’s number one men’s skincare brand, is excited to announce their . . .
Posted on 7/28/17
Elite Announces Co-Development of Four Additional Products with SunGen Pharma
NORTHVALE, N.J., July 28, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced Elite . . .
Posted on 7/28/17
Bristol-Myers Squibb (BMY) Q2 2017 Results - Earnings Call Transcript
Bristol-Myers Squibb Co. (NYSE:BMY)Q2 2017 Earnings CallJuly 27, 2017 10:30 am ETExecutivesJohn E. Elicker - Bristol-Myers Squibb Co.Giovanni Caforio - Bristol-Myers Squibb Co.Charles A. Bancroft - . . .
Posted on 7/28/17
Pernix Therapeutics Provides Business Update
MORRISTOWN, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced financial results for the three and six . . .
Posted on 7/28/17
Ortho Clinical Diagnostics Awarded Distinguished #1 Ranking for Service Performance for 2nd Year in a Row
Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced that, for the second year in a row, the Ortho Care service and . . .
Posted on 7/28/17
REPEAT/AstraZeneca and Merck Establish Strategic Oncology Collaboration
KENILWORTH, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck & Co., Inc., (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that they have entered . . .
Posted on 7/27/17
Now Is A Good Time To Buy Johnson & Johnson
Why is it so depressed now?Perhaps because “the street” got over-enthusiastic, EPS are likely to be a bit less than projected, and some analysts have “downgraded” . . .
Posted on 7/27/17
Pfizer Doesn't Want To Be Left In the Dust Of Avastin Biosimilar
Recently, Pfizer (PFE) announced it had achieved positive phase 3 results for its biosimilar candidate of Roche's (OTCQX:RHHBY) Avastin. Pfizer's biosimilar in question is known as . . .
Posted on 7/27/17
Pfizer's Worrying Trend
In my last article about Pfizer (PFE) I discussed the upcoming loss of exclusivity (LOE) of certain brands and why I did not believe these would . . .
Posted on 7/27/17
Prevea Health Partners With DocASAP
DocASAP today announced Prevea Health will utilize its online appointment scheduling solution to connect patients and providers more efficiently to large payors. This innovative healthcare collaboration . . .
Posted on 7/27/17
Eagle Pharmaceuticals Receives Complete Response Letter from FDA
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) (“Eagle” or “the Company”) announced today that it has received a Complete Response Letter from the U.S. Food and . . .
Posted on 7/26/17
Merck's Keynote Falls Flat, And That's Just Fine
With yesterday's failure of Keytruda in head and neck cancer comes yet more evidence that not all anti-PD-1 agents were created equal. It also raises fresh . . .
Posted on 7/26/17
BrainStorm Announces Agreement with University of California Irvine Medical Center
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed a definitive agreement . . .
Posted on 7/26/17
DarioHealth Partners with Byram Healthcare
DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it is expanding its insurance coverage . . .
Posted on 7/25/17
Abeona Therapeutics Appoints Juan Ruiz as Chief Medical Officer
Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies
Posted on 7/25/17
5 Things You Probably Didn't Know About Pfizer Inc.
Many people can name one of Pfizer's (NYSE:PFE) products. From over-the-counter products such as Advil and Robitussin to powerful prescription drugs such as Eliquis and Ibrance, . . .
Posted on 7/25/17
Better Buy: Johnson & Johnson vs. AbbVie
It's been a neck-and-neck race between Johnson & Johnson (NYSE:JNJ) and AbbVie(NYSE:ABBV) stocks so far in 2017. The two healthcare stocks are up by nearly identical . . .
Posted on 7/24/17
City View Pharmacy Joins AHF Pharmacy
NEW YORK--(BUSINESS WIRE)--AHF Pharmacy, a non-profit pharmacy owned and operated by AIDS Healthcare Foundation (AHF), announces today that it has acquired City View Pharmacy, an independent . . .
Posted on 7/24/17
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
$45 billion for five experimental drugs.That's how much market research firm EvaluatePharma projects the five most valuable pipeline candidates are worth right now. The firm calculated . . .
Posted on 7/24/17
Better Buy: AbbVie Inc. vs. Johnson & Johnson
U.S.-based pharmaceutical companies are enjoying a much friendlier business environment under President Trump than his predecessor. President Trump, after all, has backed away from the repeated . . .
Posted on 7/24/17
Better Buy: Celgene Corporation vs. Gilead Sciences, Inc.
Celgene (NASDAQ:CELG) and Gilead Sciences (NASDAQ:GILD) are two big biotechs facing dramatically different outlooks for the future. Their stock prices reflect that reality. Celgene's share price . . .
Posted on 7/24/17
5 Things You Probably Didn't Know About Pfizer Inc.
Many people can name one of Pfizer's (NYSE:PFE) products. From over-the-counter products such as Advil and Robitussin to powerful prescription drugs such as Eliquis and Ibrance, . . .
Posted on 7/24/17
Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the California Institute for Regenerative Medicine . . .
Posted on 7/21/17
Cyclacel Closes $15.2M Underwritten Public Offering and Full Exercise of Over-Allotment Option
BERKELEY HEIGHTS, N.J., July 21, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response . . .

